{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-252071","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2021-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.761638+00:00","generated_at":"2026-06-29T08:43:08.861375+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Design Therapeutics appoints Julie Burgess as Chief Accounting Officer","bullets":["Julie Burgess appointed Chief Accounting Officer, effective September 13, 2021.","Annual base salary of $350,000, bonus up to 35%, and stock option for 135,000 shares.","Burgess previously SVP Finance at Otonomy; brings over 25 years of experience.","Dawn Giangiulio will cease as interim principal accounting officer but remain Controller."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-252071","json":"https://secwatch.observer/filing/0001193125-21-252071.json","markdown":"https://secwatch.observer/filing/0001193125-21-252071.md","text":"https://secwatch.observer/filing/0001193125-21-252071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000119312521252071/0001193125-21-252071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000119312521252071/d172325d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T08:43:08.861375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53d726ef83","claim":"Dawn Giangiulio changed role as Interim Principal Accounting Officer at Design Therapeutics, Inc..","evidence_excerpt":"Upon the Effective Date, which is expected to be September 13, 2021, Dawn Giangiulio, the Company’s Controller and interim principal accounting officer, will discontinue serving as the Company’s interim principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000119312521252071/0001193125-21-252071-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"discontinue serving as"},{"label":"Role","value":"Interim Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"6af3aad661","claim":"Julie Burgess was appointed as Chief Accounting Officer at Design Therapeutics, Inc..","evidence_excerpt":"On August 18, 2021, the Board of Directors (the “Board”) of Design Therapeutics, Inc. (the “Company”) appointed Julie Burgess as the Company’s Chief Accounting Officer and principal accounting officer, effective upon the date she commences employment with the Company (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000119312521252071/0001193125-21-252071-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}